Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition

International Journal of Pharmaceutics

Volumn 396, Issue 1-2, 2010, Pages 149-155

  Dolenc, Andrej ^a   Govedarica, Biljana ^a   Dreu, Rok ^a   Kocbek, Petra ^a   Srčič, Stane ^a   Kristl, Julijana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Dissolution; High pressure homogenization; In vitro lipase inhibition; Melt emulsification; Nanosuspension; Obesity; Orlistat

Indexed keywords

LACTOSE; NANOPARTICLE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; ANTIOBESITY AGENT; ENZYME INHIBITOR; LACTONE; POWDER;

ARTICLE; DISSOLUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; ENZYME INHIBITION; IC 50; LASER DIFFRACTION; PARTICLE SIZE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; ATOMIC FORCE MICROSCOPY; CHEMISTRY; KINETICS; MEDICINAL CHEMISTRY; NANOTECHNOLOGY; PHARMACEUTICS; POWDER; PROCEDURES; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SURFACE PROPERTY;

ANTI-OBESITY AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; ENZYME INHIBITORS; KINETICS; LACTONES; LACTOSE; LIPASE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NANOTECHNOLOGY; POWDERS; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 77955091331     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.003     Document Type: Article

References (34)

1. Ambrus R., Kocbek P., Kristl J., Sibanc R., Rajkó R., Szabó-Révész P. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int. J. Pharm. 2009, 381:153-159.
2. Ballinger A., Peikin S.R. Orlistat: its current status as an antiobesity drug. Eur. J. Pharmacol. 2002, 440:109-117.
3. Barbier, P., Hadvary, P., Lengsfeld, H., 2002. Orlistat compositions. US 2002/0035089. Hoffman-La Roche Inc.
4. Carrière F., Renou C., Ransac S., Lopez V., De Caro J., Ferrato F., De Caro A., Fleury A., Sanwald-Ducray P., Lengsfeld H., Beglinger C., Hadvary P., Verger R., Laugier R. Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281:16-28.
5. Daggy, B.P., Mandel, K.G., 2003. Lipastatin derivative-soluble fiber tablets. US 2003/023077. GlaxoSmithKline.
6. DeLancey S. FDA Issues Early Communication About Ongoing Safety Review of Weight Loss Drug Orlistat 2009, FDA News Release, Available online on: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm180057.htm.
7. Dolenc A., Kristl J., Baumgartner S., Planinšek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm. 2009, 376:204-212.
8. Effat S., Hassan J., Abbas K.Z., Bettina Z. HPLC analysis of orlistat and its application to drug quality control studies. Chem. Pharm. Bull. 2007, 55:251-254.
9. EMEA Scientific Discussion 2005, Available online on: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Xenical/106698en6.pdf.
10. EMEA, EMEA European Public Assessment Report (EPAR) Alli, EMEA/H/C/854 2009.
11. Hadvary P., Lengsfeld H., Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem. J. 1988, 256:357-361.
12. Heck A.M., Yanovski J.A., Calis K.A. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000, 20:270-279.
13. Henness S., Perry C.M. Orlistat: a review of its use in the management of obesity. Drugs 2006, 66:1625-1656.
14. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
15. Kirat K., Burton I., Dupres V., Duprene Y. Atomic force microscopy in the characterization of drug nanoparticles. J. Microsc. 2005, 218:199-207.
16. Kocbek P., Baumgartner S., Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. 2006, 312:179-186.
17. Kocbek P., Teskač K., Brožič P., Lanišnik-Rižner T., Gobec S., Kristl J. Effect of free and in poly(e{open}-caprolactone) nanoparticles incorporated new type 1 17β-hydroxysteroid dehydrogenase inhibitors on cancer cells. Curr. Nanosci. 2010, 6:69-76.
18. Kolesnikova E.N., Glukhareva N.A. The influence of an electrolyte on micelle formation in aqueous solutions of sodium monoalkyl sulfosuccinates. Phys. Chem. Surf. Phenom. 2009, 93:2322-2324.
19. Kothamasu, S.S., Sah, A., Asapu, U.S., Arumalla, M.R., 2009. Orlistat pharmaceutical formulations. WO 2009/039157. Dr. Reddy's Laboratories Ltd.
20. Lee Y.P., Chung G.H., Rhee J.S. Purification and characterization of Pseudomonas fluorescens SIK W1 lipase expressed in Escherichia coli. Biochim. Biophys. Acta. 1993, 1169:156-164.
21. Lewis D., Liu D. A Novel In Vitro Assay Capable of Monitoring the Inhibitory Effect of Orlistat Dosages 2009, Available online on: http://www.aapsj.org/abstracts/NBC_2009/NBC09-000376.PDF.
22. Lowe M.E. Pancreatic triglyceride lipase and colipase: insights into dietary fat digestion. Gastroenterology 1994, 107:1524-1536.
23. Maeder, K., Scheibler, L.C., Steffen, H., 2004. Pharmaceutical compositions having depressed melting points. US 6,730,319. Hoffmann-La Roche Inc.
24. Mohammadi A., Haririan I., Rezanour N., Ghiasi L., Walker R.B. A stability-indicating high performance liquid chromatographic assay for the determination of orlistat in capsules. J. Chromatogr. A 2006, 1116:153-157.
25. Moon, J.M. Lee, H.-A., 2007. Pharmaceutical formulation with high stability and dissolution and manufacturing process. WO 2007/021073. Boram Pharm. Co., Ltd.
26. MU{double acute}ller R.H., Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 2004, 113:151-170.
27. Müllertz, A., 2007. Biorelevant dissolution media, solvent systems and their selection in pharmaceutics and biopharmaceutics. AAPS Series, Biotechnology: Pharmaceutical Aspects, pp. 151-177.
28. Myers, G.L., Hilbert, S.D., Boone, B.J., 2009. Film delivery system for tetrahydrolipstatin. US 2009/0104270. Hoffmann & Baron, LLP.
29. Ponchel G., Montisci M.J., Dembri A., Durrer C., Duchêne D. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur. J. Pharm. Biopharm. 1997, 44:25-31.
30. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3:785-796.
31. Saveyn H., Mermuys D., Thas O., van der Meeren P. Determination of the refractive index of water-dispersible granules for use in laser diffraction experiments. Part. Syst. Charact. 2002, 19:426-432.
32. Shah, N., Zeller, M., 1998. Tetrahydrolipstatin containing formulations. WO 98/34607. Hoffman-La Roche AG.
33. Sternby B., Hartmann D., Borgstroom B., Nilsson P. Degree of in vivo inhibition of human gastric and pancreatic lipases by orlistat (tetrahydrolipstatin, THL) in the stomach and small intestine. Clin. Nutr. 2002, 21:395-402.
34. Wang Z., Du J. Therapeutic potential of lipase inhibitor orlistat in Alzheimer's disease. Med. Hypotheses 2009, 73:662-663.